Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | CCR3 | P51677 | 3/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034621 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2POLBKDM4EALDH1A1SIGMAR1 | |
| SCHEMBL4513933 | 0.84 | HRH3 (0.67) | SMN1; SMN2POLBKDM4EALDH1A1SIGMAR1 | |
| SCHEMBL21820699 | 0.83 | ALDH1A1 (0.64) | KDM4EALDH1A1SIGMAR1MEN1KMT2A | |
| SCHEMBL19075637 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2POLBKDM4EALDH1A1SIGMAR1 | |
| SCHEMBL3150313 | 0.81 | SMN1; SMN2 (0.65) | SMN1; SMN2POLBKDM4EALDH1A1SIGMAR1 | |
| SCHEMBL21252822 | 0.81 | DRD4 (0.51) | SMN1; SMN2KDM4EALDH1A1CCR3MCHR1 | |
| SCHEMBL4513928 | 0.81 | SMN1; SMN2 (0.65) | SMN1; SMN2POLBKDM4EALDH1A1SIGMAR1 | |
| SCHEMBL21604394 | 0.80 | ALDH1A1 (0.62) | POLBALDH1A1MEN1KMT2ACCR3 | |
| SCHEMBL4034625 | 0.80 | SIGMAR1 (0.60) | SMN1; SMN2POLBKDM4EALDH1A1SIGMAR1 | |
| SCHEMBL5743274 | 0.80 | SIGMAR1 (0.59) | SMN1; SMN2POLBKDM4EALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | SMN1; SMN2 2803/4885POLB 2801/4885KDM4E 2958/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | SMN1; SMN2 2803/4885POLB 2801/4885KDM4E 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.